More Stories

Informist, Thursday, Jun. 25, 2026

 

MUMBAI – Shares of most pharmaceutical companies are expected to rise more next week on a combination of factors including the sector's relative immunity to a weak monsoon, new opportunities in the US, strong domestic sales performance, and defensive buying. However, analysts said defensive purchases during the war in West Asia have pushed up share prices of pharmaceutical companies, which may limit meaningful upside in the medium-term.         

 

Investors will turn their attention to the upcoming June quarter earnings of pharma companies. "The most important commentary, according to me, will be how they perform in (the) US and what is next (in the US product pipeline)," an analyst at a domestic brokerage said. "(Slowdown in) US business is a trend we have seen throughout last year and in (the) upcoming few quarters we'll find out whether companies have found good replacements for the drug (generic Revlimid). Largecap players reported almost no sales of the high-margin drug in the March quarter, which affected profitability in their US business sharply. 

 

"Pharmaceuticals (sector) with inelastic demand is, normally, an out-performer during deficient monsoons, VK Vijayakumar, Chief Investment Strategist, Geojit Investments Ltd, said. Some analysts added that pharmaceutical stocks may see more investments in case a lackadaisical monsoon leads to pressure on discretionary spending and consequently, on consumer-facing companies.

 

This week, the Nifty Pharma index ended over 2% higher at 24969.50 points. Cipla, Dr. Reddy's Laboratories, and Piramal Pharma rose the most among Nifty Pharma constituents and gained 5.5-6.5% during the week. Meanwhile, Wockhardt, Abbott India, and Glenmark Pharmaceuticals declined 2–3% in the week. 

 

"The Nifty Pharma index is moving north in a higher-high and higher-low formation following its breakout from a two-year-long congestion zone during the first week of May," Vipin Kumaar, assistant vice-president at Globe Capital Markets said. "Going forward, we reiterate our bullish view on the Nifty Pharma index as long as it remains above the 24000 level on a closing basis, and we expect it to test the 25600–25800 levels in the near term," he said. Kumaar suggests traders maintain a "buy on dips" trading approach. For the coming week, the analyst sees the sector finding support at 24500–24200 levels and for it to face resistance at 25600–25800 levels. 

 

TOP HEADLINES

 

* Kenyan, Ugandan authorities complete inspection of Concord Biotech facility
* Jubilant Pharmova arm gets relief of INR 654 mln in income tax dispute
* Biocon to supply insulin to Malaysia-based Duopharma Biotech's arm
* Need long-term policy to support high-value pharma sector, says NITI Aayog
* IPO Alert: Ujin Pharma files DRHP for total issue of 19.15 mln shrs
* GST officials conduct inspection at Acutaas Chemicals' Surat facility
* SPOTLIGHT: Pharma cos' Q1 margins to be hit QoQ as US-Iran war bumps up costs
* Sun Pharma buys Mumbai-based Innovcare Lifesciences for INR 2.71 bln
* Govt bans manufacture, sale, distribution of 16 fixed-dose combination drugs
* US FDA issues 5 observations to Aurobindo Pharma arm Eugia Steriles' unit

 

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	25,585.00	(-)2.40	25,968.30	25,288.30
Alkem Laboratories	5,425.00	1.00	5,522.70	5,359.70
Aurobindo Pharma	1,555.20	3.80	1,583.70	1,517.70
Biocon	416.15	0.20	430.10	407.50
Cipla	1,440.10	6.50	1,463.40	1,419.40
Divi's Laboratories	6,713.50	(-)0.40	6,793.80	6,648.80
Dr Reddy's Laboratories	1,350.50	6.20	1,379.60	1,317.40
Gland Pharma	2,314.80	5.30	2,395.50	2,262.90
GlaxoSmithKline Pharmaceuticals	2,354.80	1.00	2,411.70	2,304.70
Glenmark Pharmaceuticals	2,154.40	(-)2.70	2,212.90	2,118.50
Granules India	764.20	(-)2.90	791.60	744.80
Ipca Laboratories	1,618.30	2.10	1,675.40	1,577.40
Laurus Labs	1,450.00	2.60	1,475.70	1,425.70
Lupin	2,343.50	(-)0.30	2,411.00	2,303.20
Natco Pharma	903.70	1.70	926.80	886.40
Pfizer	4,460.70	(-)1.60	4,563.50	4,393.70
Sanofi India	3,355.60	0.40	3,452.50	3,292.50
Sun Pharmaceutical Industries	1,862.80	1.30	1,898.30	1,840.30
Torrent Pharmaceuticals	4,516.20	2.00	4,590.20	4,435.40
Zydus Lifesciences	1,101.40	2.90	1,120.70	1,086.70
Index	Levels
Nifty Pharma	24969.50	2.10	25232.30	24816.90
Nifty 50	24056.00	0.20	24341.50	23896.30
S&P BSE Sensex	77100.47	0.40	78109.00	76488.90

 

 

End

 

Reported by Eshitva Prakash

Edited by Deepshikha Bhardwaj

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000/+91 (11) 4220-1000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.